𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy and safety evaluation of loreclezole as add-on treatment in therapy-resistant epilepsy patients

✍ Scribed by T Rentmeester; J Hulsman

Publisher
Elsevier Science
Year
1991
Tongue
English
Weight
381 KB
Volume
8
Category
Article
ISSN
0920-1211

No coin nor oath required. For personal study only.

✦ Synopsis

Thirteen drug-resistant epilepsy patients received loreclezole as add-on therapy. The trial lasted 6 months. Loreclezole was dosed to reach a target plasma concentration between 1 and 3 mg/l. The seizure frequency in the total group decreased by 23%. A reduction of 50% or more was observed in four patients. These effects are most likely related to loreclezole, as doses and plasma levels of the associated anti-epileptic drugs remained unchanged during the study. Loreclezole was tolerated well and no changes in haematological or biochemical parameters were observed.

πŸ“œ SIMILAR VOLUMES

A double-blind, placebo-controlled evalu
A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures
✍ T Rentmeester; A Janssen; J Hulsman; F Scholtes; B van der Kleij; J Overweg; J M πŸ“‚ Article πŸ“… 1991 πŸ› Elsevier Science 🌐 English βš– 655 KB

Sixty-two patients with uncontrolled partial seizures participated in a 12-week, double-blind, placebo-controlled add-on-trial. Thirty-two patients received loreclezole and 30 a placebo as add-on therapy. Loreclezole was targeted at a plasma level of 1-2 mg/l. In spite of an antiepileptic therapy, u

Long-term evaluation of the efficacy and
Long-term evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures: a 1-year open follow-up
✍ T. Rentmeester; A. Janssen; J. Hulsman; F. Scholtes; B. van der Kleij; J. Overwe πŸ“‚ Article πŸ“… 1991 πŸ› Elsevier Science 🌐 English βš– 534 KB

The effect and safety of loreclezole were evaluated during a long-term follow-up trial targeting higher plasma concentrations than those of the preceding controlled trial. The result is better than in the double-blind trial, in which loreclezole doses were administered to reach plasma concentrations

Efficacy of adefovir add-on lamivudine r
Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B
✍ Han Jak Ryu; Jung Min Lee; Sang Hoon Ahn; Do Young Kim; Myoung Ha Lee; Kwang-Hyu πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 134 KB πŸ‘ 1 views

## Abstract No study has reported on the comparative effect of adefovir (ADV) add‐on lamivudine (LAM) versus switching to entecavir (ETV) in LAM‐resistant patients with chronic hepatitis B. From October 2007 to September 2008, 92 consecutive LAM‐resistant patients were enrolled (47 LAM + ADV and 45